Yoshimasa Saito

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2237163/publications.pdf

Version: 2024-02-01

46 papers

3,550 citations

236925 25 h-index 233421 45 g-index

47 all docs

47 docs citations

47 times ranked

5575 citing authors

#	Article	IF	CITATIONS
1	Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell, 2006, 9, 435-443.	16.8	1,253
2	Epigenetic Activation of Tumor Suppressor MicroRNAs in Human Cancer Cells. Cell Cycle, 2006, 5, 2220-2222.	2.6	266
3	Cancer Epigenetics: Modifications, Screening, and Therapy. Annual Review of Medicine, 2008, 59, 267-280.	12.2	241
4	Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochemical and Biophysical Research Communications, 2009, 379, 726-731.	2.1	214
5	Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma. Cell Reports, 2019, 27, 1265-1276.e4.	6.4	137
6	Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell, 2021, 28, 816-832.	11.1	133
7	An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. Cell, 2020, 183, 1420-1435.e21.	28.9	111
8	Overexpression of miR-142-5p and miR-155 in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Resistant to Helicobacter pylori Eradication. PLoS ONE, 2012, 7, e47396.	2.5	101
9	Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. Oncotarget, 2018, 9, 9925-9939.	1.8	98
10	Silencing of <i>microRNAâ€122</i> is an early event during hepatocarcinogenesis from nonâ€alcoholic steatohepatitis. Cancer Science, 2014, 105, 1254-1260.	3.9	71
11	Epigenetic Alterations and MicroRNA Misexpression in Cancer and Autoimmune Diseases: a Critical Review. Clinical Reviews in Allergy and Immunology, 2014, 47, 128-135.	6. 5	71
12	microRNA-34a as a Therapeutic Agent against Human Cancer. Journal of Clinical Medicine, 2015, 4, 1951-1959.	2.4	69
13	Dysfunctional Gastric Emptying With Down-regulation of Muscle-Specific MicroRNAs in Helicobacter pylori-Infected Mice. Gastroenterology, 2011, 140, 189-198.	1.3	66
14	Efficacy of Sitafloxacin-Based Rescue Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies. Antimicrobial Agents and Chemotherapy, 2012, 56, 1643-1645.	3.2	50
15	Gut microbiota-mediated generation of saturated fatty acids elicits inflammation in the liver in murine high-fat diet-induced steatohepatitis. BMC Gastroenterology, 2017, 17, 136.	2.0	46
16	Generation of human hepatic progenitor cells with regenerative and metabolic capacities from primary hepatocytes. ELife, 2019, 8, .	6.0	46
17	Alterations of epigenetics and micro <scp>RNA</scp> in hepatocellular carcinoma. Hepatology Research, 2014, 44, 31-42.	3.4	42
18	Interferonâ€associated retinopathy in a uniform regimen of natural interferonâ€Î± therapy for chronic hepatitis C. Liver, 2001, 21, 192-197.	0.1	39

#	Article	IF	Citations
19	Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor. Journal of Cellular Physiology, 2001, 187, 392-401.	4.1	39
20	Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma. International Journal of Molecular Sciences, 2017, 18, 1111.	4.1	39
21	MicroRNAs in Hepatobiliary and Pancreatic Cancers. Frontiers in Genetics, 2011, 2, 66.	2.3	36
22	Prominent Steatosis with Hypermetabolism of the Cell Line Permissive for Years of Infection with Hepatitis C Virus. PLoS ONE, 2014, 9, e94460.	2.5	32
23	Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system. Scientific Reports, 2018, 8, 2821.	3.3	30
24	Role of CTCF in the regulation of microRNA expression. Frontiers in Genetics, 2012, 3, 186.	2.3	29
25	Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori. Cancers, 2019, 11, 116.	3.7	27
26	First-line eradication for <i>Helicobacter pylori</i> -positive gastritis by esomeprazole-based triple therapy is influenced by <i>CYP2C19</i> genotype. World Journal of Gastroenterology, 2015, 21, 13548.	3.3	27
27	Epigenetic silencing of Lgr5 induces senescence of intestinal epithelial organoids during the process of aging. Npj Aging and Mechanisms of Disease, 2018, 4, 1.	4.5	26
28	Inhibition of DNA Methylation Suppresses Intestinal Tumor Organoids by Inducing an Anti-Viral Response. Scientific Reports, 2016, 6, 25311.	3.3	23
29	Reduction of câ€ <i>myc</i> expression by an antisense approach under Cre/loxp switching induces apoptosis in human liver cancer cells. Journal of Cellular Physiology, 2001, 188, 56-66.	4.1	21
30	Interferon regulatory factor 1 promoter polymorphism and response to type 1 interferon. Journal of Cellular Biochemistry, 2001, 81 , $191-200$.	2.6	19
31	Development of a novel microRNA promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs. Biochemical and Biophysical Research Communications, 2012, 426, 33-37.	2.1	18
32	Cluster microRNAs miRâ€194 and miRâ€215 suppress the tumorigenicity of intestinal tumor organoids. Cancer Science, 2017, 108, 678-684.	3.9	17
33	Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets. IScience, 2019, 21, 624-637.	4.1	15
34	Establishment of an organoid bank of biliary tract and pancreatic cancers and its application for personalized therapy and future treatment. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1906-1910.	2.8	13
35	Derangement of ghrelin secretion after longâ€ŧerm highâ€fat diet feeding in rats. Hepatology Research, 2013, 43, 1105-1114.	3.4	12
36	Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy. Therapeutic Innovation and Regulatory Science, 2018, 52, 718-723.	1.6	12

#	Article	IF	CITATIONS
37	Dual effects of the Nrf2 inhibitor for inhibition of hepatitis C virus and hepatic cancer cells. BMC Cancer, 2018, 18, 680.	2.6	12
38	Glucose Depletion Enhances the Stem Cell Phenotype and Gemcitabine Resistance of Cholangiocarcinoma Organoids through AKT Phosphorylation and Reactive Oxygen Species. Cancers, 2019, 11, 1993.	3.7	10
39	Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions. Cancer Cell, 2022, 40, 226-230.	16.8	10
40	Establishment and Long-Term Culture of Organoids Derived from Human Biliary Tract Carcinoma. STAR Protocols, 2020, 1, 100009.	1.2	6
41	The Effects of Continuous and Withdrawal Voluntary Wheel Running Exercise on the Expression of Senescence-Related Genes in the Visceral Adipose Tissue of Young Mice. International Journal of Molecular Sciences, 2021, 22, 264.	4.1	6
42	Optimal Anti-cancer Drug Profiles for Effective Penetration of the Anti-cancer Drug Market by Generic Drugs in Japan. Therapeutic Innovation and Regulatory Science, 2018, 52, 442-448.	1.6	5
43	Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis. Hepato-Gastroenterology, 2005, 52, 1491-6.	0.5	5
44	microRNA-mediated resistance to hypoglycemia in the HepG2 human hepatoma cell line. BMC Cancer, 2016, 16, 732.	2.6	4
45	Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model. Journal of Clinical Biochemistry and Nutrition, 2018, 63, 123-128.	1.4	2
46	A strategy aimed at low risk ESD and Four days clinical pathway for superficial gastric neoplasias. Progress of Digestive Endoscopy, 2008, 73, 58-61.	0.0	0